Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate cancer applications including an unexpected fundamental discovery that might ignite interest as a new research area in cancer metastasis. The study analysed blood samples from 81 prostate cancer patients and showed that Parsortix captured so-called EMTing cancer cells, those circulating tumour ce
16 Jun 2017
A boost for prostate cancer indication
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A boost for prostate cancer indication
ANGLE plc (AGL:LON) | 14.0 0 (-1.8%) | Mkt Cap: 36.5m
- Published:
16 Jun 2017 -
Author:
Dr Jonas Peciulis -
Pages:
2
Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate cancer applications including an unexpected fundamental discovery that might ignite interest as a new research area in cancer metastasis. The study analysed blood samples from 81 prostate cancer patients and showed that Parsortix captured so-called EMTing cancer cells, those circulating tumour ce